CSIMarket
 


Royalty Pharma Plc  (RPRX)
Other Ticker:  
 
 

RPRX's Net Income Growth by Quarter and Year

Royalty Pharma Plc's Net Income results by quarter and year




RPRX Net Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 717.59 -610.03 53.67
III Quarter September - 122.08 220.41 221.80
II Quarter June - 351.34 491.60 806.76
I Quarter March -4.27 509.09 128.08 158.98
FY   -4.27 1,700.10 230.06 1,241.21



RPRX Net Income first quarter 2024 Y/Y Growth Comment
Royalty Pharma Plc in the first quarter 2024 recorded net loss of $ -4.27 millions.

Looking into first quarter 2024 results within Major Pharmaceutical Preparations industry 3 other companies have achieved higher Net Income growth. While Royalty Pharma Plc' s Net Income no change of % ranks overall at the positon no. 99 in the first quarter 2024.




RPRX Net Income ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - - - -88.76 %
III Quarter September - -44.61 % -0.63 % -64.47 %
II Quarter June - -28.53 % -39.06 % 34.02 %
I Quarter March - 297.48 % -19.44 % -
FY   - 638.98 % -81.46 % -27.07 %

Financial Statements
Royalty Pharma Plc's first quarter 2024 Net Income $ -4.27 millions RPRX's Income Statement
Royalty Pharma Plc's first quarter 2023 Net Income $ 509.09 millions Quarterly RPRX's Income Statement
New: More RPRX's historic Net Income Growth >>


RPRX Net Income (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - 487.8 % - -75.8 %
III Quarter September - -65.25 % -55.16 % -72.51 %
II Quarter June - -30.99 % 283.82 % 407.46 %
I Quarter March - - 138.64 % -66.69 %
FY (Year on Year)   - 638.98 % -81.46 % -27.07 %




Net Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #4
Healthcare Sector #11
Overall #99

Net Income Y/Y Growth Statistics
High Average Low
638.96 % 51.38 % -81.46 %
(Dec 31 2023)   (Dec 31 2022)
Net Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #4
Healthcare Sector #11
Overall #99
Net Income Y/Y Growth Statistics
High Average Low
638.96 % 51.38 % -81.46 %
(Dec 31 2023)   (Dec 31 2022)

Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Royalty Pharma Plc's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RPRX's I. Quarter Q/Q Net Income Comment
I. Quarter 2024 results of -4.27 millions by Royalty Pharma Plc come out even less good considering the 717.59 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Royalty Pharma Plc achieved highest sequential Net Income growth. While Royalty Pharma Plc's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RPRX's I. Quarter Q/Q Net Income Comment
I. Quarter 2024 accomplishment of -4.27 millions by Royalty Pharma Plc come out even worse if you take a look at net loss 717.59 millions a quarter before.

Within Major Pharmaceutical Preparations industry Royalty Pharma Plc achieved highest sequential Net Income growth. While Royalty Pharma Plc's Net Income growth quarter on quarter, overall rank is .


Royalty Pharma Plc's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Net Income 12 Months Ending $ 1,186.73 $ 1,700.09 $ 372.47 $ 470.81 $ 611.07
Y / Y Net Income Growth (TTM) 94.2 % 638.96 % -58.33 % -47.4 % -49.51 %
Year on Year Net Income Growth Overall Ranking # 1386 # 403 # 1485 # 1158 # 1016
Seqeuential Net Income Change (TTM) -30.2 % 356.43 % -20.89 % -22.95 % 165.61 %
Seq. Net Income Growth (TTM) Overall Ranking # 114 # 393 # 720 # 984 # 703




Cumulative Net Income growth Comment
Assuming the Royalty Pharma Plc's fiscal year would have ended in Mar 31 2024, Royalty Pharma Plc would have reprted above average annual Net Income growth of 94.2% year on year, of $ 1,187 millions.
This marks a slow-down of the companys growth trends and from the 638.96% surge in Dec 31 2023.

In the Healthcare sector 88 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 403 to 1386.

Net Income TTM Q/Q Growth Statistics
High Average Low
638.96 %
51.38 %
-81.46 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 4
Healthcare Sector # 89
Overall # 1386

Net Income TTM Y/Y Growth Statistics
High Average Low
638.96 %
51.38 %
-81.46 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 11
S&P 500 # 114
Cumulative Net Income growth Comment
Assuming the Royalty Pharma Plc's fiscal year would have ended in Mar 31 2024, Royalty Pharma Plc would have reprted above average annual Net Income growth of 94.2% year on year, of $ 1,187 millions.
This marks a slow-down of the companys growth trends and from the 638.96% surge in Dec 31 2023.

In the Healthcare sector 88 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 403 to 1386.

Net Income TTM Q/Q Growth Statistics
High Average Low
638.96 %
51.38 %
-81.46 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 4
Healthcare Sector # 89
Overall # 1386

Net Income TTM Y/Y Growth Statistics
High Average Low
638.96 %
51.38 %
-81.46 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 11
S&P 500 # 114




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
RPRX's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for RPRX's Competitors
Net Income Growth for Royalty Pharma Plc's Suppliers
Net Income Growth for RPRX's Customers

You may also want to know
RPRX's Annual Growth Rates RPRX's Profitability Ratios RPRX's Asset Turnover Ratio RPRX's Dividend Growth
RPRX's Roe RPRX's Valuation Ratios RPRX's Financial Strength Ratios RPRX's Dividend Payout Ratio
RPRX's Roa RPRX's Inventory Turnover Ratio RPRX's Growth Rates RPRX's Dividend Comparisons



Companies with similar Net Income surge for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2024
Iqvia Holdings Inc -0.35%$ -0.346 millions
Cadre Holdings inc -1.06%$ -1.057 millions
Exelixis Inc -1.95%$ -1.950 millions
Quest Diagnostics Inc-4.15%$ -4.147 millions
Progyny Inc -4.41%$ -4.412 millions
3m Company-4.89%$ -4.893 millions
Mettler Toledo International Inc-5.79%$ -5.794 millions
Utah Medical Products Inc-6.12%$ -6.122 millions
Abbott Laboratories-7.06%$ -7.056 millions
Entera Bio Ltd -7.90%$ -7.900 millions
National Research Corporation-8.69%$ -8.688 millions
Regeneron Pharmaceuticals Inc -11.71%$ -11.714 millions
Baxter International Inc -13.33%$ -13.333 millions
Phibro Animal Health Corporation-16.30%$ -16.302 millions
West Pharmaceutical Services Inc -17.64%$ -17.643 millions
Atrion Corporation-19.89%$ -19.885 millions
Tenx Keane Acquisition-19.93%$ -19.927 millions
Catalyst Pharmaceuticals Inc -21.28%$ -21.283 millions
American Shared Hospital Services-35.00%$ -35.000 millions
Amedisys Inc-41.41%$ -41.411 millions
Dariohealth Corp -44.05%$ -44.055 millions
Fonar Corporation-44.64%$ -44.638 millions
Envista Holdings Corporation-46.12%$ -46.119 millions
Viatris Inc -49.31%$ -49.310 millions
Pro dex Inc -50.11%$ -50.114 millions
Avantor Inc -50.29%$ -50.288 millions
Ir med Inc -51.33%$ -51.333 millions
Privia Health Group Inc -52.26%$ -52.265 millions
Orgenesis Inc -57.20%$ -57.202 millions
Oramed Pharmaceuticals Inc -57.52%$ -57.519 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com